

ATTORNEY DOCKET NO. MSK.P-038-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Application No: 09/960,665
Filing Date: September 21, 2001
First Named Inventor: Rosen, et al.
Confirmation No.: 5586
Group Art Unit: 1624
Examiner Name: KIFLE, Bruck
Attorney Docket No.: MSK.P-038-2

Examiner's Initials	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
B.K.	Yang, et al., "Disruption of the EF-2 Kinase/Hsp90 Protein Complex: A Possible Mechanism to Inhibit Glioblastoma by Geldanamycin"; Cancer Research 61, May 15, 2001, pages 4010-4016.
D.K.	Okabe, et al., "In Vivo Antitumor Activity of Herbimycin A, a Tyrosine Kinase Inhibitor, Targeted Against BCR/ABL Oncoprotein in Mice Bearing BCR/ABL-Transfected Cells"; Leukemia Research, Vol. 18, No. 11, 1994, pages 867-873.
D.K.	Kelland, et al., "DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90"; Journal of the National Cancer Institute, Vol. 91, No. 22, November 17, 1999, pages 1940-1949.
B.K.	Burger, et al., "Response of Human Melanomas to 17-AAG is Associated with Modulation of the Molecular Chaperone Function of Hsp90"; Proceeding of the American Association for Cancer Research, Vol. 41, March 2000, page 447.
B.K.	Fritz, L., "Notes on 17-AAG Clinical Trials from ASCO Meeting, May 2001, San Francisco".
D.K.	Solit, et al., "17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts"; Clinical Cancer Research, Vol. 8, May 2002, pages 986-993.
D.K.	Nguyen, et al., "Enhancement of Paclitaxel-Mediated Cytotoxicity in Lung Cancer Cells by 17-Allylamino Geldanamycin: In Vitro and In Vivo Analysis"; The Society of Thoracic Surgeons, 2001, pages 371-379.
B.K.	Nguyen, et al., "Modulation of Metastasis Phenotypes of Non-Small Cell Lung Cancer Cells by 17-Allylamino 17-Demethoxy Geldanamycin"; The Society of Thoracic Surgeons, 2000, pages 1853-1860.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner: Bruck Date Considered: 6/18/04